Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept

Journal of Rheumatology

Volumn 38, Issue 7, 2011, Pages 1441-1446

  Van Dijken, Trudy D ^a   Vastert, Sebastiaan J ^a   Gerloni, Valeria M ^b   Pontikaki, Irene ^b   Linnemann, Kristina ^c   Girschick, Hermann ^d   Armbrust, Wineke ^e   Minden, Kirsten ^f   Prince, Femke H M ^g   Kokke, Freddy T M ^a   Nieuwenhuis, Edward E S ^a   Horneff, Gerd ^h   Wulffraat, Nico M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^h Asklepios Klinik Sankt Augustin   (Germany)

Author keywords

Etanercept; Incidence; Inflammatory bowel disease; Juvenile idiopathic arthritis

Indexed keywords

ETANERCEPT;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DENMARK; DRUG WITHDRAWAL; ENTERITIS; FINLAND; GERMANY; HUMAN; INCIDENCE; INDETERMINATE COLITIS; ITALY; JUVENILE RHEUMATOID ARTHRITIS; NETHERLANDS; PRESCHOOL CHILD; PRIORITY JOURNAL; REGISTER; SCHOOL CHILD; SYMPTOM; ULCERATIVE COLITIS;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DENMARK; FEMALE; FINLAND; GERMANY; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INFANT; INFLAMMATORY BOWEL DISEASES; ITALY; MALE; NETHERLANDS; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79959958989     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100809     Document Type: Article

References (32)

1. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. New Engl J Med 2000;342:763-9. (Pubitemid 30151920)
2. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: Twent-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8. (Pubitemid 35453523)
3. Dekker L, Armbrust W, Rademeker CM, Prakken B, Kuis W, Wulffraat NM. Safety of anti-TNF alpha therapy in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2004;22:252-8. (Pubitemid 38444819)
4. Nair B, Raval G, Mehta P. TNF-á inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 2007;82:1022-4. (Pubitemid 350004395)
5. Ramos-Casals m, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008;22:847-61.
6. Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 2008;26:471-5. (Pubitemid 352003220)
7. Prince FHM, Twilt M, ten Cate R, van Rossum MAJ, Armbrust W, Hoppenreijs EPAH, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41.
8. Haraoui B, Krelenbaum M. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: Possible mechanisms of action. Semin Arthritis Rheum 2009;39:176-81.
9. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94. (Pubitemid 33022088)
10. Dallocchio A, Canioni D, Ruemmele F, Quesne A, Coazec JY, Bouvier R, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology 2010;49:1694-8.
11. Kokkonen J, Arvonen M, Vahasalo P, Karttunen T. Intestinal immune activation in juvenile idiopathic arthritis and connective tissue disease. Scand J Rheumatol 2007;36:386-9. (Pubitemid 350034814)
12. Ruemmele FM, Prieur AM, Talbotec C, Goulet O, Schmitz J. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutrition 2004;39:203-6.
13. Oh J, Arkfeld DG, Horwitz DA. Development of Crohn's disease in a patient taking etanercept. J Rheumatol 2005;32:752-3. (Pubitemid 40524713)
14. Fouache D, Goeb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology 2009;48:761-4.
15. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2. (Pubitemid 38160763)
16. Sawczenko A, Sandhu BK, Logan RFA, Jenkins H, Taylor CJ, Mian S, et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 2001;357:1093-4. (Pubitemid 32322542)
17. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25.
18. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 2008;67:1145-52.
19. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7. (Pubitemid 36238089)
20. Cohen R, Robinson D, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis 2008;14:738-43.
21. Picco P, Gattorno M, Marchese N, Vignola S, Sormani MP, Barabino A, et al. Increased gut permeability in juvenile chronic arthritides. A multivariate analysis of the diagnostic parameters. Clin Exp Rheumatol 2000;18:773-8.
22. Baeten D, De Keyser F, Mielants H, Veys EM. Immune linkages between inflammatory bowel disease and spondyloarthropathies. Curr Opin Rheumatol 2002;14:342-7. (Pubitemid 34693975)
23. Mielants H, Veys EM, Cuvelier C, Devos M. Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 1996;10:147-64. (Pubitemid 26122079)
24. Mielants H, Veys EM, Joos R, Cuvelier C, De Vos M, Proot F. Late onset pauciarticular juvenile chronic arthritis: relation to gut inflammation. J Rheumatol 1987;14:459-65. (Pubitemid 17116923)
25. Jose FA, Garnett EA, Vittinghoff E, Ferry GD, Winter HS, Baldossano RN, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2009;15:63-8.
26. Zaag-Loonen HJ, Casparie M, Tarniniau JAJM, Escher JC, Pereira RR, Derkx HHF. The incidence of pediatric inflammatory bowel disease in the Netherlands: 1999-2001. J Pediatr Gastroenterol Nutrition 2004;38:302-7.
27. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53. (Pubitemid 43764536)
28. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26. (Pubitemid 34429950)
29. Sieper J, van den Brande J. Diverse effects of infliximab and etanercept on T lymphocytes. Semin Arthritis Rheum 2005;34:23-7.
30. Zou JX, Brown J, Sieper J. Immunological basis for the use of TNF alpha-blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin Exp Rheumatol 2002;20 Suppl 28:S34-S37.
31. Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNF alpha receptors. Ann Rheum Dis 2001;60:133-9. (Pubitemid 32102204)
32. Van den Brande JMH, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterol 2003;124:1774-85. (Pubitemid 36666774)